Neogen Corporation shares have surged 101.1% over the past year, sharply outperforming its industry's 30.4% decline and the S&P 500's 22.5% gain. The rally has been driven by strength in the Food Safety segment, where third-quarter fiscal 2026 revenues reached 157.6 million dollars with core revenue growth of 4%, supported by indicator testing, culture media, and pathogen test kits. The company also raised its full-year fiscal 2026 revenue guidance to a range of 857 million to 860 million dollars, up from 845 million to 855 million dollars. Recent product launches, including the Neogen MPNTray water testing system and the Listeria Right Now assay, along with progress integrating the former 3M Food Safety business, have bolstered investor confidence. However, Neogen faces headwinds from input cost inflation, global logistics disruptions, and freight cost increases of 1.5 million dollars per quarter, while carrying 793 million dollars in total outstanding debt against 159.9 million dollars in cash.
Neogen CorporationFood Safety segment revenue growth and raised guidance driven by product demand.
Integra LifeSciences Holdings
Globus Medical
Phibro Animal Health Corporation